lanaphylactoid' reactions of laryngeal oedema or even shock and cardiac arrest. The overall incidence of side effects is 10 to 20% for nausea, 0 I to 1*4% for urticaria and vomiting, and 0-6 to 1% for severe reactions. 2 
Fluorescein, [spiro (isobenzofurin-I (3H), 9' -(9H) = xanthem]-3-one-3'6' dihvdroxv, is made by heating phthaleic anhvdride with resorcinol. It is a vellowish red powder which is soluble in water, alcohol, glvcerol, dimethvl formamide. and 85% formic acid, but is insoluble or very sparingly soluble in chloroform, ethvl ether. benzene, and xylene. The sodium salt, molecular weight 376.27, is freely soluble in water and gives an intense yellowish green fluorescence in blue or ultraviolet light down to a concentration of 0-02 ppm.
An aqueous solution of sodium fluorescein given intravenously now forms a major part of the assessment of many retinal disorders. 5 ml of 10% or 3 ml of 20% or 25% solution is injected rapidly intravenously. It is adsorbed on to albumin and other plasma proteins in the blood stream lanaphylactoid' reactions of laryngeal oedema or even shock and cardiac arrest. The overall incidence of side effects is 10 to 20% for nausea, 0 I to 1*4% for urticaria and vomiting, and 0-6 to 1% for severe reactions. 2 
Materials and methods
At the Manchester Royal Eye Hospital a record of adverse reactions to intravenous fluorescein administered in retinal photographic investigations has been routine. Concern was raised recently when an increase from 6-8% for January to July 1980 to 12-7% for January to July 1981 was noted in the total number of adverse reactions ( This analysis revealed the presence of a significant amount of an industrial solvent, dimethyl formamide (DMF), in the fluorescein. The DMF was detected by mass spectrometry and measured by nuclear magnetic resonance spectroscopy. Two samples of25% sodium fluorescein showed 11% and 8-5% molar DMF with respect to fluorescein. A sample of 20% sodium fluorescein from the same manufacturing source showed a similar percentage of DMF. Two samples of 25% sodium fluorescein from a different source made up in our own hospital pharmacy showed no evidence of DMF. Discussion DMF is used in the purification to pharmaceutical standards of crude sodium fluorescein, and it would appear that the incomplete removal of the solvent from the finished powder was responsible for the adverse reactions. DMF is a substance readily absorbed following inhalation or skin contact, and is not intended for intravenous infusion. At lower levels of exposure to DMF by inhalation, direct contact or ingestion, nausea, and vomiting may, result. Neurotoxicity, abdominal pain, hepatomegaly, hepatic necrosis, and kidney damage are seen in higher levels of exposure. 3 Attempts to find a cause for the adverse reactions to fluorescein in the past have also pointed to impurities in the sodium fluorescein. Yannuzzi et al. 4 found following chromatographic analysis that the presence of impurities increased the incidence of commonly reported side effects of fluorescein. The presence of small amounts of DMF, however, is not readily detected by chromatographic analysis, the use of sophisticated columns being required. Nor is DMF identifiable by fluorescent analytical techniques.
Other workers2 attempted to find an allergic cause for the reactions but with limited success.
Further work would have to be done to link DMF directly with the increased number of adverse reactions to fluorescein. However, the presence of DMF, a toxic contaminant in the fluorescein used in the January to July 1981 batches cannot be disputed. Since reverting to the use of purified 25% sodium fluorescein with confirmed absence of DMF, a sequence of 256 cases has shown none of the violent adverse reactions previously experienced with the contaminated batch. The incidence of nausea and vomiting reactions reverting to around 5%.
Following notification of the DHSS, users of fluorescein have been circularised warning of the content of DMF in certain batches of the dye. Regulations controlling the permissible exposure to DMF are at present under review. Subsequent to our discovery DMF in fluorescein for intravenous use has been eliminated by obtaining correctly purified sodium fluorescein. 
